Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 10/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 8/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PSIP1 | O75475 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1583079 | 0.80 | CHRM2 (0.50) | CHRM2CHRM5CHRM3TSHRGSTO1 | |
| SCHEMBL6318357 | 0.76 | CA2 (0.48) | CHRM2CHRM5CHRM3TSHR | |
| SCHEMBL10455034 | 0.76 | PSIP1 (0.74) | GAAPSIP1 | |
| SCHEMBL46155 | 0.73 | TSHR (0.72) | CHRM2CHRM5CHRM3TSHRGSTO1 | |
| SCHEMBL17688656 | 0.73 | PSIP1 (0.52) | CHRM2CHRM5CHRM3GAAPSIP1 | |
| SCHEMBL17688628 | 0.73 | PSIP1 (0.52) | CHRM2CHRM5CHRM3GAAPSIP1 | |
| SCHEMBL10181940 | 0.73 | RORC (0.62) | GAAPSIP1RORC | |
| SCHEMBL6302182 | 0.73 | CHRM2 (0.67) | CHRM2CHRM5CHRM3GAATSHR | |
| SCHEMBL17688567 | 0.73 | PSIP1 (0.52) | CHRM2CHRM5CHRM3GAAPSIP1 | |
| SCHEMBL14185372 | 0.72 | CHRM2 (0.50) | CHRM2CHRM5CHRM3GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114230523-A | Benzimidazole derivatives as modulators of ROR-gamma | 生命医药有限责任公司 | 2022-03-25 | — | — | CN | disclosed |
| EP-3939974-A1 | MODULATORS OF ROR-GAMMA | Vitae Pharmaceuticals, LLC (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-3408268-B1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS LLC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-11008340-B2 | Modulators of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3377482-B1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS LLC (US) | 2021-05-12 | — | — | EP | disclosed |
| US-20210094940-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2021-04-01 | — | — | US | disclosed |
| US-10829481-B2 | Benzimidazole derivatives as modulators of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200339566-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. | 2020-10-29 | — | — | US | disclosed |
| US-20190352286-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2019-11-21 | — | — | US | disclosed |
| US-20190322687-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC (US) | 2019-10-24 | — | — | US | disclosed |
| US-9796710-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796710-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-3207043-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | Vitae Pharmaceuticals, Inc. (US) | 2017-08-23 | — | — | EP | disclosed |
| WO-2017132432-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2017-08-03 | — | — | WO | disclosed |
| WO-2017132432-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2017-08-03 | — | — | WO | disclosed |
| US-20170081327-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2017-03-23 | — | — | US | disclosed |
| US-20170081327-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2017-03-23 | — | — | US | disclosed |
| US-9481674-B1 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| WO-2016061160-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2016-04-21 | — | — | WO | disclosed |
| WO-2016061160-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2016-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352286-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | RORB, RORC, RORA | CHRM2 2052/4885CHRM5 2726/4885CHRM3 1316/4885 |
| US-11008340-B2 | Modulators of ROR-gamma | RORC, RORB, RORA | CHRM2 1783/4885CHRM5 2622/4885CHRM3 1458/4885 |
| US-10829481-B2 | Benzimidazole derivatives as modulators of ROR-gamma | RORB, RORC, RORA | CHRM2 2353/4885CHRM5 3212/4885CHRM3 1877/4885 |
| US-20190322687-A1 | MODULATORS OF ROR-GAMMA | RORC, RORB, RORA | CHRM2 1783/4885CHRM5 2622/4885CHRM3 1458/4885 |
| US-20170081327-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | CHRM2 1678/4885CHRM5 2507/4885CHRM3 1530/4885 |
| US-20210094940-A1 | MODULATORS OF ROR-GAMMA | RORC, RORB, RORA | CHRM2 1581/4885CHRM5 2316/4885CHRM3 1269/4885 |
| US-20200339566-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | CHRM2 2186/4885CHRM5 2859/4885CHRM3 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.